Phentermine/topiramate for the treatment of obesity;Fentermina/topiramato (qsymia) para el tratamiento de obesidad

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages 340-349

  Smith, Steven M ^a   Meyer, Melissa ^b   Trinkley, Katy E ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Exempla Saint Joseph Hospital   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GLUCOSE; PHENTERMINE PLUS TOPIRAMATE; TRIACYLGLYCEROL;

ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; COMORBIDITY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW; TACHYPHYLAXIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; DRUG COMBINATIONS; FRUCTOSE; HUMANS; OBESITY; PHENTERMINE;

EID: 84875194493     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R501     Document Type: Article

References (21)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
2. Centers for Disease Control and Prevention. Obesity and overweight for professionals: childhood data. www.cdc.gov/obesity/data/childhood.html (accessed 2012 Jul 21).
3. National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, 1998. www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf (accessed 2012 Aug 20).
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-41.
5. Qnexa New Drug Application. Department of Health and Human Services: 2010. www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM292317.pdf (accessed 2012 Jul 10).
6. Food and Drug Administration. FDA drug safety communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor-PatientsandProviders/ucm213038.htm (accessed 2012 Jul 20).
7. Product information. Adipex-p (phentermine). Sellersville, PA: TEVA Pharmaceuticals, July 2005.
8. Langlois KJ, Forbes JA, Bell GW, et al. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res 1974;16:289-96.
9. Product information. Qsymia (phentermine/topiramate). Winchester, KY: VIVUS Inc., July 2012.
10. Product information. Topamax (topiramate). Titusville, NJ: Janssen Pharmaceuticals, January 2009.
11. Ben-Menachem E, Axelsen M, Hohanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11:556-62.
12. Allison D, Gadde K, Garvey WT, et al. Controlled release phentermine/topiramate in severely obese adults: a randomized, controlled trial (EQUIP). Obesity 2011;20:330-42.
13. Gadde K, Allison D, Ryan D, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52.
14. Garvey T, Ryan D, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308.
15. Brownell KD. The LEARN program for weight management. 10th ed. Dallas, TX: American Health Publishing Company, 2004.
16. Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research-limitations of methods, measurements, and medications. JAMA 2006;295: 826-8.
17. Product information. Qsymia (phentermine/topiramate CR). www.qsymia. com/hcp/(accessed 2012 Sept 21).
18. Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
19. Smith SR, Weissman NJ, Anderson CM, et al. Multi-center, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56.
20. Hurrne KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm 2011;68:2029-37.
21. Micromedex Healthcare Series. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. (accessed 2012 Sept 25).